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ABSTRACT 
 
There are few more devastating complications of musculoskeletal trauma than 
compartment syndrome (CS). It occurs secondary to elevated pressure within a 
closed osseofascial compartment, leading to microvascular dysfunction, hypo-
perfusion of the tissues, cellular anoxia and ultimately cell death. The aim of this 
thesis was to prove that CS leads to a systemic inflammatory response, and to 
examine the specific cytokines/chemokines associated with CS. Twenty-four 
cytokines/chemokines were measured in a rat model of CS. Additionally, 
microvascular dysfunction, tissue injury and inflammatory response following the 
neutralization of pro-inflammatory cytokine, TNF-α, at the time of fasciotomy 
were assessed using intravital video microscopy (IVVM). The results of our 
studies were the first to confirm that CS is associated with an acute inflammatory 
response, and that neutralization of TNF-α at the time of fasciotomy provides 
some protection against tissue injury due to CS.  
 
 
 
Keywords: compartment syndrome, microvascular dysfunction, systemic 
cytokine/chemokine release, ischemia-reperfusion, tissue injury, 
inflammation, TNF-α. 
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CHAPTER 1: INTRODUCTION 
 
1.1 COMPARTMENT SYNDROME 
Compartment syndrome (CS) results from increased pressure within a 
closed osseofascial compartment; microvascular compromise, cellular anoxia 
and ultimately cell death ensues (Whitesides, Haney et al. 1975, Mubarak, Owen 
et al. 1978, Rorabeck and Clarke 1978, Matsen, Winquist et al. 1980, Hartsock, 
O'Farrell et al. 1998). CS is a surgical emergency, whereby fasciotomy is the only 
effective treatment (Tzioupis, Cox et al. 2009).  
The etiology of CS is varied and commonly includes fractures, burns, 
crush injuries, ischemia-reperfusion injury, exertion, and prolonged limb 
compression. Less frequent causes of CS include bleeding disorders (Hope and 
McQueen 2004), lithotomy position (Mathews, Perry et al. 2001), hypothyroidism 
(Hsu, Thadhani et al. 1995), and snake bites (Vigasio, Battiston et al. 1991). 
 
1.2 DIAGNOSIS 
The diagnosis of CS is currently rooted in clinical signs and symptoms. 
Prompt diagnosis is critical in order to minimize long-term complications. A high 
suspicion must be maintained at all times; knowledge of the early clinical signs 
and symptoms, as well as a recognition of high-risk patients are vital to its timely 
diagnosis (Matsen, Winquist et al. 1980, McQueen, Gaston et al. 2000). Risk 
factors include male gender, young age, tibial fracture, high-energy forearm 
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fracture, femoral diaphyseal fractures, bleeding diathesis, and anticoagulation 
(McQueen, Gaston et al. 2000).    
Two of the hallmark clinical signs of early CS include pain out of 
proportion to the injury and pain on passive stretch (PPS) of the affected 
compartment (Whitesides and Heckman 1996). In children, or in patients whose 
level of consciousness is altered, progressively increasing analgesia 
requirements may be an early sign of developing CS (Bae, Kadiyala et al. 2001). 
Pain out of proportion to the injury and PPS are often the only findings that 
precede neurologic dysfunction of the affected compartment. Unfortunately the 
sensitivity of these clinical signs in combination is alarmingly low (13 - 19%), 
while the specificity is high (97%) (Whitesides and Heckman 1996, Ulmer 2002). 
The absence of pain and PPS is, perhaps, more useful in ruling out CS (Ulmer 
2002) than diagnosing it when they are present.   
A palpably tense compartment, resulting from increased intra-
compartmental pressure (ICP), is recognized as an early physical sign of CS 
(Mubarak, Owen et al. 1978). Any patient being evaluated, or who is at high risk 
for CS, should have their dressings or cast removed for thorough assessment. 
Serial examination is also paramount, as the onset of CS is unpredictable.  
It is important to note that the absence of a distal pulse and/or pallor of the 
affected limb are not features of CS. Likewise, paresis and/or paralysis of the 
muscles of the involved compartment are late signs of CS (Matsen and Clawson 
1975, Ulmer 2002). These are important distinctions to draw, as waiting for all 
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clinical signs and symptoms to be present for diagnosis would lead to poor 
functional outcomes, and increased morbidity and mortality.  
As an adjunct to the physical examination, intra-compartmental pressure 
monitoring is available. In patients who are unable to communicate verbally, for 
example pediatric or obtunded patients, invasive compartment pressure 
monitoring can provide valuable objective information in diagnosing acute CS 
(Gelberman, Garfin et al. 1981, Hargens, Akeson et al. 1989). While there are 
multiple methods of measuring compartment pressures, the use of electronic 
transducer-tipped systems are the most accurate and are not dependent on limb 
position or height of the transducer (McDermott, Marble et al. 1984, Willy, 
Gerngross et al. 1999). 
While ICP monitoring can serve as a valuable adjunct in the diagnosis of 
acute CS, there remains no consensus regarding the threshold at which 
fasciotomy is necessary. Multiple absolute pressure thresholds have been 
suggested, and include 30 mmHg (Mubarak, Owen et al. 1978), 40 mmHg 
(Schwartz, Brumback et al. 1989), and 45 mmHg (Matsen, Winquist et al. 1980). 
A differential pressure threshold has been popularized, which theorizes that 
tissue ischemia begins when the difference between the ICP and the diastolic 
blood pressure is 20 mmHg (Whitesides, Haney et al. 1975).  This differential 
pressure threshold has since been expanded to 30 mmHg based on 
retrospective observation that this value led to no missed cases of CS (McQueen 
and Court-Brown 1996). The differential pressure threshold is useful clinically in 
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hypotensive trauma patients, and has a lower overall rate of fasciotomy when 
compared to the absolute pressure threshold (McQueen and Court-Brown 1996). 
The diagnosis of CS requires a thorough evaluation of patients, 
maintenance of a high suspicion, awareness of risk factors, and if any doubt 
exists, frequent serial examinations with the use of invasive ICP monitoring. To 
date there is no reliable objective diagnostic test for CS; therefore clinical 
judgment remains at the forefront of diagnosis in order to prevent the 
catastrophic complications of a late diagnosis or a misdiagnosis.  
 
1.3 TREATMENT  
CS is a surgical emergency, as it is both a limb- and life-threatening 
condition. Treatment involves emergent surgical decompression of the affected 
limb by fasciotomy, regardless of the underlying cause of CS.  CS, however, 
occurs most frequently following fracture of the tibia; approximately 6% of 
patients under the age of 35 with a tibial diaphyseal fracture develop 
compartment syndrome (McQueen, Gaston et al. 2000).  
There are multiple described techniques for fasciotomy of the lower leg, 
with the two-incision technique being the preferred method (Appendix C). In brief, 
it involves incising and releasing the fascial layer that surrounds the affected 
compartment. This facilitates tissue swelling, allowing the compartments to 
expand and therefore decreasing the ICP. All non-viable tissue is debrided, 
wounds are left open, and a repeat debridement is performed 48-72 hours later. 
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At the second operation, wounds are either closed primarily, with skin grafting, or 
occasionally with more advanced reconstructive techniques.  
 
1.3.1 Anatomy of the Lower Leg  
The lower leg has four distinct osseofascial compartments: anterior, 
lateral, deep posterior, and superficial posterior (Figure 1.1). The anterior              
compartment includes the extensor muscles of the foot and ankle. The lateral 
compartment contains the peroneal muscles, which evert the foot. The posterior 
compartments, both deep and superficial, include the flexor muscles of the foot 
and ankle. 
 
1.4 COMPLICATIONS OF COMPARTMENT SYNDROME 
CS is both a limb and life-threatening condition, and despite appropriate 
and timely treatment, devastating complications can ensue. In a systematic 
review of 1920 cases of CS, overall 5.5% of patients required an amputation, and 
there was a 3.3% CS-associated mortality rate (Hayakawa, Aldington et al. 
2009). Timing of fasciotomy is critical: when comparing fasciotomy within 6 hours 
to delayed fasciotomy beyond 12 hours, there was a higher rate of amputation 
(14% vs. 3.2%) and death (4.3% vs. 2.0%) (Hayakawa, Aldington et al. 2009). A 
retrospective review of 336 combat casualties in Iraq and Afghanistan over a 20-
month period found that delayed fasciotomy resulted in double the rate of 
amputations, and increased the mortality rate threefold, as compared with 
patients who had early fasciotomy (Ritenour, Dorlac et al. 2008). 
	   7	  
 
 
Figure 1.1. Cross-section of the lower leg. The lower leg contains two bones 
(tibia and fibula) and is divided into four distinct osseofascial 
compartments: (1) anterior compartment (containing tibialis 
anterior, extensor hallucis longus, extensor digitorum longus, 
peroneus tertius, the deep peroneal nerve and the anterior tibial 
vessels); (2) lateral compartment (containing peroneus longus, 
peroneus brevis, superficial peroneal nerve); (3) deep posterior 
compartment (contains tibialis posterior, flexor digitorum longus, 
and flexor hallucis longus, tibial nerve and posterior tibial vessels); 
(4) superficial posterior compartment (contains gastrocnemius, 
soleus, and plantaris, and the sural nerve).  
Reproduced with permission from Lawendy and Sanders (2010). 
!
! 8!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Cross-section of the lower leg. The lower leg consists of two 
bones (tibia and fibula) and 10 major muscles (tibialis anterior, extensor 
digitorum longus, extensor hallucis longus, peroneus longus, peroneus brevis, 
soleus, gascrocnemius, tibialis posterior, flexor digitorum longus, flexor hallucis 
longus). The muscles are separated by fascia into four compartments (anterior, 
lateral, superficial posterior and deep posterior). 
Reproduced with permission from Lawendy and Sanders (2010).
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Infection is a common complication following fasciotomy, with high rates of 
7.3% even when treated early, versus 28% if fasciotomy is delayed greater than 
12 hours (Williams, Luchette et al. 1997). A retrospective study of 60 patients 
found that 70% of patients had long-term neurologic dysfunction following 
fasciotomy (62% weakness, 66% paresthesia, 71% dysaesthesia) (Dover, 
Memon et al. 2012). Fitzgerald et al performed a retrospective review of patient 
outcomes over an 8-year period, and reported that 77% of their patient 
population had residual sensory deficits around their wounds, and 10% had 
chronic pain (Fitzgerald, Gaston et al. 2000). In another study 15.4% of all 
patients have residual pain at rest, and 26.9% have pain with exertion following 
CS (Frink, Klaus et al. 2007). 
 
1.5 PATHOPHYSIOLOGY 
The pathophysiological mechanism of the tissue injury seen in 
compartment syndrome remains only partially understood. The literature 
supports raised ICP as the initial insult, which then leads to microvascular 
dysfunction. Damage to the microcirculatory system results in hypo-perfusion, 
causing cellular anoxia and muscle death (Sheridan and Matsen 1975, 
Whitesides, Haney et al. 1975, Rorabeck and Clarke 1978, Matsen, Winquist et 
al. 1980, Harvey, Sanders et al. 2012). In contrast with complete ischemia, CS 
causes tissue necrosis despite a patent macrocirculatory system: patients with 
CS almost always have a palpable distal pulse (Seddon 1966, Lawendy, Bihari et 
al. 2015).  
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Live in vivo imaging using intravital video microscopy (IVVM) of the 
microcirculatory system in an animal model of CS, has demonstrated that raised 
ICP causes significant impairment in capillary perfusion. Under normal 
physiological conditions there is continuous flow through the capillary beds. 
Raised ICP, however, causes a shift in perfusion toward non-perfused capillaries 
(NPC), and intermittently perfused capillaries (IPC) (Lawendy, Sanders et al. 
2011, Lawendy, Bihari et al. 2015). Decreased tissue perfusion leads to 
inefficient nutrient and gas exchange for the metabolic demands of the tissue. 
NPCs have no ability for nutrient or gas exchange, and represent a state of 
ischemia. The presence of some continuously perfused (CPC), IPC, and NPC in 
the same muscle bed therefore suggests that CS is a low-flow ischemic state.  
IVVM has also been able to demonstrate that the microvascular 
dysfunction seen secondary to raised ICP is associated with rapid activation of 
leukocytes in post-capillary venules, suggesting the inflammatory pathway may 
play a role in the tissue injury seen in CS (Lawendy, Sanders et al. 2011, 
Lawendy, Bihari et al. 2015). We know from complete ischemia and reperfusion 
(I/R) literature that the re-introduction of oxygenated blood into an ischemic 
muscle bed causes a significant activation of leukocytes (Gute, Ishida et al. 1998, 
Lakshminarayanan, Lewallen et al. 2001). It has been well documented in 
complete I/R that increasing ischemia time causes increasing accumulation of 
activated leukocytes in the post-capillary venules. Leukocyte activation leads to 
increased vascular permeability to plasma protein leakage, tissue edema, and 
increased interstitial pressure. This increased interstitial pressure is believed to 
	   10	  
physically compress capillaries, leading to failure of capillaries to reperfuse upon 
restitution of blood flow to ischemic tissue. The microvascular dysfunction 
associated with reperfusion injury is known as no-reflow phenomenon, whereby 
despite successful resolution of ischemia there is impaired nutrient and gas 
exchange to meet the metabolic demands of the tissue (Sexton, Korthuis et al. 
1990, Kurose, Anderson et al. 1994, Gute, Ishida et al. 1998). A strong 
correlation has been noted between the number of leukocytes in the capillaries of 
post ischemic tissue and the percentage of capillaries exhibiting no-reflow 
(Engler, Dahigren et al. 1986, Barroso-Aranda, Schmid-Schonbein et al. 1988, 
Del Zoppo, Schmid-Schonbein et al. 1991, Gute, Ishida et al. 1998).  
Further support that activated leukocytes are involved in no-reflow 
phenomenon is observed in leukopenic models of complete I/R. The 
microvascular dysfunction of no-reflow in re-perfused myocardium, brain, and 
skeletal muscle tissue has been abolished in neutrophil-deplete models of 
complete I/R (Schmid-Schonbein, Shih et al. 1975, Barroso-Aranda, Schmid-
Schonbein et al. 1988, Jerome, Smith et al. 1993). Leukopenia does not, 
however, appear to be protective in restoring or maintaining perfusion following a 
CS insult (Lawendy, Bihari et al. 2015). Additionally, a greater impairment to the 
metabolic state and structural integrity of skeletal muscles has been shown in 
canines subjected to 3 hours of hind limb raised ICP, followed by 2 hours of 
reperfusion, compared to animals undergoing 3 hours of complete ischemia, 
followed by 2 hours of reperfusion (Heppenstall, Scott et al. 1986). These 
findings suggest that while compartment syndrome falls within the spectrum of 
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ischemia – reperfusion injury, the pathophysiology of tissue injury is distinct from 
that of complete I/R.  
 
1.6 LEUKOCYTE ACTIVATION 
Live in vivo studies have demonstrated that the microvascular dysfunction 
associated with CS occurs in conjunction with leukocyte accumulation and 
activation in the post capillary venules (Lawendy, Bihari et al. 2015). Leukocyte 
activation occurs via a series of events, which ultimately results in extravasation 
of the leukocyte from the blood stream to the extravascular tissue. With the 
reintroduction of oxygenated blood after an ischemic insult, reactive oxygen 
species (ROS) are generated, which promote a pro-inflammatory stimulus. 
Additionally, ROS modify the expression of adhesion molecules on the surface of 
leukocytes and endothelial cells, resulting in their activation (Gute, Ishida et al. 
1998). In the initial phase of leukocyte activation, leukocytes come into contact 
with the endothelial cell surface and begin to roll along the endothelium of the 
post-capillary venule following tissue injury or inflammation (Atherton and Born 
1973, Carlos and Harlan 1994). Leukocytes are considered rolling if they remain 
in contact with the vessel wall but do not remain static. A family of three proteins, 
known as selectins, mediates rolling; they include E- (endothelial), P- (platelet), 
and L- (leukocyte) selectin, where E- and P-selectin are expressed by stimulated 
endothelial cells, and L-selectin is expressed by leukocytes (Bevilacqua and 
Nelson 1993, Carlos and Harlan 1994).  
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In the second phase of leukocyte activation, leukocytes become firmly 
adherent to the endothelium. A leukocyte is considered adherent if it remains 
fixed to the vessel wall. Adhesion is modulated via leukocyte integrins; the 
transmembrane glycoprotein family CD11/CD18 has been identified as the most 
likely integrins to modulate neutrophilic adhesion (Dana, Fathallah et al. 1991, 
Gute, Ishida et al. 1998). Binding of chemokines, cytokines, or chemoattractants 
can increases the affinity of the integrins for endothelial adhesion proteins 
(Carlos and Harlan 1994). The counter-receptor for CD11/CD18 expressed by 
endothelial cells is the intercellular adhesion molecule-1 (ICAM-1) (Horgan, Ge et 
al. 1991, Ma, Lefer et al. 1992). 
Once firmly adherent to the endothelium, activated leukocytes extravasate 
into the subendothelial matrix towards sites of inflammation or injury, where they 
are thought to be responsible for parenchymal injury via release of oxidants and 
hydrolytic enzymes. Additionally, extravasated leukocytes disrupt the 
microvascular barrier, increasing the permeability of intravascular proteins into 
the extravascular space and causing tissue edema (Gute, Ishida et al. 1998).  
 
1.7 SYSTEMIC CYTOKINES/CHEMOKINES 
Cytokines comprise a group of cell-derived secreted proteins that effect 
the interactions and communications between cells (Feghali and Wright 1997, 
Zhang and An 2007). Cytokine is a general term, and includes cytokines 
produced by lymphocytes (lymphokines), and monocytes (monokines). 
Chemokines are a subset of cytokines with chemotactic properties. Interleukins 
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are cytokines that are produced by leukocytes, and exert their effects on other 
leukocytes. Cytokines can exert their effects on the cell which secretes them 
(autocrine action), on nearby cells (paracrine action), or at distant sites 
(endocrine action) (Zhang and An 2007).  
Cytokines are responsible for the make-up of the cellular infiltrate, cellular 
activation, and the initiation of the systemic response to inflammation. Most 
cytokines are multifunctional and have redundant activities. They may act 
synergistically or antagonistically, and can exhibit both negative and positive 
regulatory effects on their target cells. Cytokines bind with high affinity to cell 
surface receptors on their target cells, initiating a series of intracellular signal 
transduction pathways (Feghali and Wright 1997). 
Pro-inflammatory cytokines are predominantly produced by activated 
macrophages, and result in the upregulation of inflammatory reactions (Zhang 
and An 2007). A number of cytokines have been implicated in mediating acute 
inflammatory reactions. Interleukin 1 (IL-1), and tumor necrosis factor alpha 
(TNF-α) are two of the primary cytokines that mediate acute inflammation, and 
have pro-inflammatory properties (Feghali and Wright 1997).  
 
1.8 TUMOR NECROSIS FACTOR ALPHA 
TNF-α is a potent pro-inflammatory cytokine released by macrophages  
(innate immune cells) following trauma, inflammation, or infectious stimulation 
(Stein and Gordon 1991). TNF-α plays a role in the regulation of cell proliferation, 
survival, differentiation, and apoptosis (Parameswaran and Patial 2010). TNF-α 
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has been found in multiple I/R studies to be acutely upregulated following the 
initiation of reperfusion (Caty, Guice et al. 1990, Brock, Lawlor et al. 1999, 
Krishnadasan, Naidu et al. 2003). TNF-α exerts its effects through two 
transmembrane receptors: TNF receptor 1 (TNFR1), and TNF receptor 2 
(TNFR2). TNFR1 is ubiquitously expressed in most tissues, where TNFR2 is 
found mainly on cells of the immune system (Banner, D'Arcy et al. 1993). 
Activation of TNFR1 by TNF-α results in a complex series of signalling pathways, 
ultimately leading to altered gene transcription in the activated cell 
(Parameswaran and Patial 2010). TNFR1 can couple with the adaptor protein 
Fas-associated death domain (FADD), which causes progression toward 
apoptosis, i.e. programmed cell death (Wallach 1997, Jiang, Wang et al. 2009). 
In the context of acute limb ischemia, signals in the TNF-α/TNFR1 pathway have 
been found to be upregulated, however it was unknown whether this would 
induce apoptosis. In 2009, Jiang et al. induced hind limb ischemia in TNFR1 
knockout mice; they found that blocking the TNF-α/TNFR1 pathway prevented 
the activation of death-related proteins downstream to TNF-α, and significantly 
decreased cell death (Jiang, Wang et al. 2009).  
The role of TNFR2 is less clear; however, it has been reported to play a 
role in the proliferation of lymphoid cells and it appears to contribute to TNF-α-
induced E-selectin, vascular adhesion molecule 1 (VCAM-1), and ICAM-1 
expression (Chandrasekharan, Siemionow et al. 2007).  
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1.9   CELL DEATH 
The activation of TNFR1 is able to signal cell death via its cytoplasmic 
death domain in a multitude to cell types (Wajant, Pfizenmaier et al. 2003). TNF-
α has been shown to initiate cell death by either apoptosis or necroptosis (Wu, 
Tan et al. 2011).  Apoptosis is a form of genetically programmed cell death, 
whereby cell death occurs without the initiation of the inflammatory pathway. It 
plays an essential role in embryonic development, tissue homeostasis, immune 
function, tumor suppression, infection resistance, and eliminating damaged cells 
(Reed 2000, Walsh 2014).  
Briefly, apoptosis involves a highly regulated series of events which 
involves chromatin condensation, nuclear fragmentation, plasma blebbing, and 
cell shrinkage. Cellular fragments are then removed via phagocytosis without 
triggering the inflammatory response (Reed 2000). Caspases are a family of 
intracellular cysteine proteases critical to triggering apoptosis. Caspases are 
present in virtually all cells in their inactive forms, and must be triggered to 
assume their active state (Reed 2000, Walsh 2014).  
Apoptosis can be triggered by activation of either the extrinsic or intrinsic 
pathways. The intrinsic pathway involves the release of cytochrome C from the 
mitochondria into the cytoplasm, which then activates a variety of caspases 
(Walsh 2014). The extrinsic pathway is initiated by TNF-α binding to TNFR1, 
whereby the cytoplasmic death domain recruits other death domain associated 
proteins, ultimately inducing caspase activity and apoptosis (Wang, Du et al. 
2008, Wu, Tan et al. 2011). 
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An additional mechanism of programmed cell death is inducible via 
activation of TNFR1 by TNF-α. It has been termed programmed necrosis, or 
necroptosis, and occurs independent of caspase activity (Linkermann and Green 
2014, Walsh 2014). Necroptosis ensues when there is pan-caspase inhibition, 
and the cell is, therefore, unable to undergo apoptosis (Linkermann and Green 
2014). It is typically associated with pathological conditions including infection, 
ischemia-reperfusion injury, stroke, myocardial infarction, pancreatitis, 
Alzheimer’s, and inflammatory bowel disease, (Vandenabeele, Galluzzi et al. 
2010, Linkermann and Green 2014). The initiation of necroptosis by death 
receptors associated with TNFR1 requires the kinase activity of receptor-
interacting protein 1 (RIP1), and RIP3. In contrast to apoptosis, necroptosis 
involves the disintegration of mitochondrial, lysosomal and plasma membranes 
which are then engulfed by macrophages, and elicits an immune response 
(Vandenabeele, Galluzzi et al. 2010). Necroptotic cell death has been associated 
with the tissue injury that results following I/R. We can deduce from these 
findings that this pathway of programmed cell death is also responsible for the 
tissue injury associated with CS. 
 
1.10 AIM OF THESIS 
The pathophysiology underlying the tissue injury seen in CS remains 
largely unknown. It has been well documented in complete I/R literature that 
activation of the systemic inflammatory system plays a significant role in the 
parenchymal damage associated with reperfusion injury. CS appears to be a low-
	   17	  
flow ischemic insult; therefore, we have extrapolated from this that the 
inflammatory response may contribute to the tissue injury associated with CS. 
Leukopenic animal models of CS have demonstrated a significant reduction in 
leukocyte activation and tissue injury associated with raised ICP (Lawendy, 
Bihari et al. 2015). 
The aim of this thesis was, therefore, to investigate the suspected 
inflammatory cytokine/chemokine release in response to CS. It has been 
previously hypothesized that TNF-α may play a role in the microvascular 
dysfunction associated with CS. Therefore, we undertook the evaluation of the 
microvascular dysfunction, tissue injury, and inflammatory response following 
neutralization of TNF-α at the time of fasciotomy.   
We hypothesized that a CS insult is associated with a systemic activation 
of the inflammatory response, and that neutralization of TNF-α would decrease 
the microvascular dysfunction associated with CS.  
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CHAPTER 2: COMPARTMENT SYNDROME AS AN INFLAMMATORY PROCESS 
 
2.1 INTRODUCTION 
 Compartment syndrome (CS), one of the most devastating consequences of 
musculoskeletal trauma, is defined as elevated pressure within a closed 
osseofascial compartment (McQueen, Gaston et al. 2000). CS commonly occurs 
following fracture of the lower leg; approximately 6% of patients under the age of 35 
with a tibial diaphyseal fracture will develop CS (McQueen, Gaston et al. 2000). 
CS is a surgical emergency, and the gold standard treatment involves 
fasciotomy of the affected limb in order to relieve the raised intra-compartmental 
pressure (ICP) (Harvey, Sanders et al. 2012). Despite appropriate and early 
fasciotomy, complications of CS include neurologic injury, decreased function of the 
extremity, ischemic contractures, infection, loss of limb, and death (Giannoudis, 
Nicolopoulos et al. 2002, Dover, Memon et al. 2012, Fry, Wade et al. 2013). 
The pathophysiology of CS is only partly understood. Current teachings 
propose that raised ICP compromises the microcirculation, which ultimately leads to 
decreased oxygen delivery, tissue anoxia, and cell death (Sheridan and Matsen 
1975, Whitesides, Haney et al. 1975, Rorabeck and Clarke 1978). In contrast to 
complete ischemia, however, CS induces myonecrosis and nerve injury despite 
patent blood vessels and a palpable distal pulse (Seddon 1966). CS is, therefore, 
considered a ‘low flow’ ischemic state, which results in microvascular hypo-perfusion 
that is insufficient to meet the metabolic demands of the tissues (Lawendy, Sanders 
et al. 2011). By comparison, complete ischemia, results in macro-vascular 
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dysfunction, with a loss of distal pulses. Complete ischemia has both a defined 
ischemic time and onset of reperfusion once blood flow is restored, while in ‘low flow’ 
ischemia there is no cessation of blood flow. Therefore, the true onsets of the 
ischemic insult, as well as the onset of reperfusion, are unknown.  
The initiation of the inflammatory response has been well delineated in 
complete ischemia-reperfusion injury, as seen primarily in organ transplant and re-
vascularization procedures (Forbes, Harris et al. 1996, Harris and Skalak 1996). CS 
falls within the spectrum of ischemia-reperfusion injury. Therefore, we have 
postulated that the ongoing ischemia-reperfusion injury, associated with CS, will also 
cause an early and concurrent initiation of the systemic inflammatory cascade. 
A previous study by our group had assessed CS-induced microvascular 
dysfunction, tissue injury, and leukocyte activation in a leukopenic rat model 
(Lawendy et al. 2015). We demonstrated that leukopenia provided significant 
protection against CS-induced muscle injury, concurrent with a significant reduction 
in leukocyte activation. It did not, however, provide any protection against the 
microvascular dysfunction associated with CS. 
We hypothesized that the injury seen as a result of CS is secondary to both 
ischemia and the early initiation of the inflammatory cascade, with ongoing and 
simultaneous reperfusion, thereby inducing the systemic inflammatory response. 
The purpose of our study was to examine the suspected inflammatory 
cytokine/chemokine release in response to CS. 
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2.2 METHODS 
2.2.1 Animal Handling and Care 
 Male Wistar rats were utilized for these experiments. Animals had access to 
food and water ad libitum. Animal housing, care, and associated protocols were 
conducted in agreement with the Canadian Council on Animal Care. The Animal Use 
Subcommittee at The University of Western Ontario approved the animal protocol for 
this study.  
 
2.2.2 Experimental Protocol 
 Five rats (body weight 180 - 250g) were anesthetized with inhalational 
isoflurane (5% induction, 2% maintenance, titrated as needed to maintain an 
adequate level of general anesthesia) in a 1:1 O2:N2 mixture. The left carotid artery 
was cannulated for continuous blood pressure monitoring, blood sampling, and fluid 
replacement. A rectal probe was inserted to monitor core body temperature, which 
was adjusted using a heat lamp, as needed. We used a normotensive and 
normothermic model of CS, where the mean arterial blood pressure was maintained 
at 100mmHg, and core body temperature at 37°C. 
 
2.2.3 Compartment Syndrome 
 Isotonic saline was infused into the anterior compartment of the right hind 
limb via a 24-gauge catheter in order to elevate the ICP, as previously described 
(Lawendy, Sanders et al. 2011). The ICP was measured by an electronic 
compartmental pressure monitoring system (Synthes USA, Paoli, PA), which was 
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inserted into the posterior compartment through a 14-gauge angiocatheter (Figure 
2.1). The ICP was maintained at 30-40mmHg for 120 minutes; this was followed by 
fasciotomy and then 45 minutes of reperfusion.  
 
2.2.4 Blood Sampling 
 Blood samples were collected from the indwelling carotid line. At each 
sampling time, 0.3ml of blood was extracted and replaced with an equal volume of 
normal saline. Blood sampling was done as follows: (1) at the time of carotid artery 
cannulation, for baseline levels; (2) after 1hr of CS; (3) 2hrs of CS; following (4) 10-; 
(5) 20-; (6) 30-; and (7) 45-mintues of reperfusion. All blood samples were stored on 
ice during the surgical procedure and then centrifuged at 1200xg for 15min at room 
temperature. Serum was collected and placed into clean micro-centrifuge tubes and 
stored at -800C. 
  
2.2.5 Cytokines/Chemokines Sampled 
 Serum samples were diluted at 1:5 dilution, as per the manufacturer’s 
instructions, and run on a 24-plex xMAP Luminex assay (Millipore, Billerica MA) for 
simultaneous testing of the following pro-inflammatory cytokines/chemokines: Tumor 
Necrosis Factor (TNF)-α, Interleukin (IL)-1α, IL-1β, IL-2, IL-5, IL-12p70, IL-13, IL-17, 
IL-18, Interferon Gamma (IFN-Υ), Eotaxin, Interferon Gamma-Induced Protein (IP)-
10, Macrophage Inflammatory Protein (MIP)-1α, Leptin, Monocyte Chemotactic 
Protein (MCP)-1, Growth Regulated Oncogene/Keratinocyte-Derived Chemokine 
(GRO/KC), RANTES.  
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Fig 2.1. Experimental Set-Up for Rat Model of CS. Rat was anesthetized with 
isoflurane, and left carotid artery cannulated for blood pressure 
monitoring. Isotonic saline was infused into the anterior compartment 
to raise ICP, with continuous ICP monitoring via 14G catheter in the 
posterior compartment. 
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White blood cell growth factors Granulocyte Macrophage-Colony Stimulating Factor 
(GM-CSF) and Granulocyte-Colony Stimulating Factor (G-CSF) were tested, along 
with the angiogenic cytokine Vascular Endothelial Growth Factor (VEGF). 
Additionally, a number of anti-inflammatory cytokines were tested and included IL-4, 
IL-9, IL-10, as well as IL-6, which can be both pro- and anti-inflammatory.  
 
2.2.6 Statistical Analysis 
 The numbers were expressed as means±SEM. Repeated measures one-way 
analysis of variance testing (ANOVA) was used to compare each sample within the 
time course to its baseline levels, with Newman-Keuls multiple comparison post hoc 
test where appropriate (GraphPad Prism V5.0, San Diego, CA). Sample size 
calculation was performed using StatMate (GraphPad Software Inc., San Diego, 
CA), with power set at 85%. Statistical significance was defined as p<0.05. 
 
 
2.3 RESULTS 
2.3.1 Detectable Cytokines/Chemokines 
 Of the 24 cytokines/chemokines sampled, 14 were detectable using xMAP 
Luminex technology. These included TNF-α, IL-1α, IL-1β, IL-12p70, IL-13, IL-18, 
IFN-γ, Eotaxin, MIP-1α, Leptin, MCP-1, GRO/KC, IL-10, and IL -6. 
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2.3.2 Significantly Elevated Cytokines/Chemokines 
 Six of the 14 cytokines/chemokines that were detectable were significantly 
elevated from their baseline levels: TNF-α significantly increased across all time 
points, from 32.1±2.6pg/ml at baseline to 226.3±31.0pg/ml, 335.7±64.7pg/ml, 
317.7±68.5pg/ml, 338.4±85.5pg/ml, 403.3±131.5pg/ml, and 798.7±370.7pg/ml at 1hr 
of CS, 2hrs of CS, 10min, 20min, 30min, and 45min of reperfusion, respectively 
(p<0.05) (Figure 2.2). 
 IL-1β levels were significantly elevated from the baseline of 26.7±26.7pg/ml to 
97.7±32.1pg/ml, 141.3±13.1pg/ml, 102.2±22.1pg/ml, and 119.9±17.6pg/ml at 1hr of 
CS, 2hrs of CS, 10, and 20 minutes of reperfusion, respectively (p<0.05). By 30 and 
45minutes of reperfusion, systemic IL-1β levels returned to the baseline levels of 
46.0±46.0pg/ml and 61.2±31.7pg/ml, respectively (Figure 2.3). 
 GRO/KC levels were significantly elevated from 990.2±190.8pg/ml at 
baseline, to 27217.0±6939.0pg/ml, 29073.0±7169.0pg/ml, 31115.0±7961.0pg/ml, 
32494.0±5763.0pg/ml, and 35529.0±2624.0pg/ml at 2hrs of CS, 10, 20, 30, and 45 
minutes of reperfusion, respectively (p<0.05).  After 1hr of CS, GRO/KC level was 
2985.0±1172.0pg/ml (n.s.) (Figure 2.4). 
 MCP-1 levels were significantly elevated from the baseline level of 
313.4±31.4pg/ml to 698.8±300.6pg/ml, 803.4±374.6pg/ml, 926.0±549.6pg/ml, 
849.7±395.3pg/ml, and 778.2±289.4pg/ml after 2hrs of CS, 10, 20, 30, and 45 
minutes of reperfusion, respectively (p<0.05). After 1hr of CS, MCP-1 level was 
305.0±34.0pg/ml (n.s.) (Figure 2.5). 
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 MIP-1α levels were significantly elevated across all time points, from 0.0 
pg/ml at baseline, to 41.9±34.3pg/ml, 84.8±36.6pg/ml, 68.9 ±14.5pg/ml, 
81.4±21.3pg/ml, 103.3±24.9pg/ml, and 131.1±29.3pg/ml after 1hr of CS, 2hrs of CS, 
10, 20, 30, and 45 minutes of reperfusion, respectively (p<0.05) (Figure 2.6). 
IL-10 levels were significantly elevated across all time points, from the 
baseline of 68.4±68.4pg/ml to 676.9±358.7pg/ml, 1138.0±372.3pg/ml, 
898.4±225.8pg/ml, 591.7±225.2pg/ml, 727.0±180.5pg/ml, and 1023.0±97.3pg/ml 
after 1hr of CS, 2hrs of CS, 10, 20, 30, and 45 minutes of reperfusion, respectively 
(p<0.05) (Fig 2.7).  
 
2.4 DISCUSSION 
 CS, a complication of muscle trauma, poses a particular challenge. The 
pathophysiological mechanisms of CS are complex and not fully understood. The 
purpose of this study was to determine if the low-flow ischemia associated with CS 
would result in the systemic activation of the inflammatory response.  
 
2.4.1 Systemic Inflammatory Response 
Acute inflammation is characterized by the activation of circulating leukocytes, 
whereby activation results in leukocyte rolling and adhesion. Activated leukocytes 
produce reactive oxygen species, and release cytokines and chemokines, as a 
consequence of the reintroduction of oxygen into ischemic tissue (Harkin, Barros 
D'sa A et al. 2001). The generation of reactive oxygen species ultimately triggers 
cellular apoptosis and necrosis (Schlag, Harris et al. 2001). 
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Fig 2.2. Time Course of TNF-α Expression in Rat Model of CS. CS induced 
a significant increase in systemic TNF-α after 1hr and 2hrs of raised 
ICP, and at each time point measured during reperfusion. Peak TNF-α 
levels were seen after 45-minutes of reperfusion with a 25-fold 
increase from baseline (*p<0.05 from baseline, repeated measures 
one-way ANOVA).  
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Fig 2.3. Time Course of IL-1β Expression in Rat Model of CS. CS induced a 
significant increase in systemic IL-1β after 1hr and 2hrs of raised ICP, 
and through 20 minutes of reperfusion. Levels were no longer 
significantly elevated from baseline after 30 or 45 minutes of 
reperfusion (*p<0.05, repeated measures one-way ANOVA).  
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Fig 2.4. Time Course of GRO/KC Expression in Rat Model of CS. CS 
induced a significant increase in systemic GRO/KC after 2hrs of raised 
ICP, and at each time point measured throughout reperfusion (*p<0.05, 
repeated measures one-way ANOVA). 
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Fig 2.5. Time Course of MCP-1 Expression in Rat Model of CS. CS induced 
a significant increase in systemic MCP-1 after 2hrs of raised ICP, and 
at each time point measured throughout the reperfusion period 
(*p<0.05, repeated measures one-way ANOVA). 
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Fig 2.6. Time Course of MIP-1α Expression in Rat Model of CS. CS induced 
a significant increase in systemic MIP-1α after 1hr of raised ICP, and at 
each time point measured throughout the 45 minutes reperfusion 
period (*p<0.05, repeated measures one-way ANOVA). 
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Fig 2.7. Time Course of IL-10 Expression in Rat Model of CS. CS induced a 
significant increase in systemic IL-10 after 1hr of CS, and at each time 
point measured throughout the 45-minute reperfusion period (*p<0.05, 
repeated measures one-way ANOVA). 
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It has been well documented that revascularization following complete 
ischemia results in the initiation of acute inflammation (Gute, Ishida et al. 1998, Lum 
and Roebuck 2001, Schlag, Harris et al. 2001). Using a model of complete hind limb 
ischemia, animals rendered neutropenic prior to the onset of ischemia had a delay in 
the onset of muscle injury, and a decrease in the magnitude of injury seen (Forbes, 
Harris et al. 1996). Additionally, an earlier and more rapid onset of leukocyte 
activation was shown in a rodent model of partial ischemia when compared to 
complete ischemia (Heppenstall, Scott et al. 1986, Forbes, Harris et al. 1996, 
Lakshminarayanan, Lewallen et al. 2001).  
 
2.4.2 Systemic Cytokine/Chemokine Release 
Cytokines are intercellular signaling peptides released from stimulated 
leukocytes, which induce the production of other cytokines and cell surface 
receptors through their effects on gene transcription (Cannon 2000, Grivennikov, 
Kuprash et al. 2006).   
Chemokines are a family of chemotactic cytokines, which recruit monocytes, 
neutrophils, and lymphocytes to sites of injury and inflammation. Chemotaxis is 
induced through the activation of G-protein-coupled receptors, and the receptors that 
a given leukocyte expresses usually determines the chemokines to which it will 
respond (Charo and Taubman 2004). Chemokines are secreted by a variety of cell 
types, including leukocytes, fibroblasts, and endothelial cells (Roebuck, Carpenter et 
al. 1999). 
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While an increasing amount of literature exists to suggest that the initiation of 
the systemic inflammatory response plays a role in the myonecrosis associated with 
CS, no study to date has directly measured the cytokine/chemokine release induced 
by CS. A normothermic and normotensive model of CS was used in order to remove 
the possibility of a systemic inflammatory response secondary to hypoperfusion and 
shock. 
Our study has confirmed that CS induces a systemic cytokine/chemokine 
release. Of the 24 cytokines/chemokines measured, 14 were detectable. Of the 14 
detected, 12 were pro-inflammatory, 1 was anti-inflammatory, and 1 had both a pro- 
and an anti-inflammatory effect.  
Six of the 14 cytokines/chemokines that were detectable were significantly 
elevated from their baseline levels after 2hrs of CS. These include TNF-α, IL-1β, 
GRO/KC, MCP-1, MIP-1α, and IL-10. 
 TNF-α is a pro-inflammatory cytokine, and one of the first cytokines released 
with the initiation of inflammation. It serves as a chemoattractant for neutrophils, up-
regulation of downstream cytokine/chemokine production, and it promotes the 
expression of adhesion molecules (Ascer, Gennaro et al. 1992, Yi and Ulich 1992, 
Seekamp, Warren et al. 1993, Krishnadasan, Naidu et al. 2003, Zhang, Hu et al. 
2005).  
IL-1β is a pro-inflammatory cytokine, and it is produced by activated 
macrophages. It is involved in multiple cellular functions including cell proliferation, 
differentiation, and apoptosis (Gao, Madi et al. 2014).  
	   41	  
GRO/KC is a pro-inflammatory cytokine, and it is produced by macrophages 
and neutrophils. It serves to induce neutrophil chemotaxis. It is also seen in high 
levels in chronic inflammatory states such as chronic obstructive pulmonary disease 
(COPD) and rheumatoid arthritis (Bechara, Chai et al. 2007).  
MCP-1 is a pro-inflammatory cytokine whose primary role is to recruit 
monocytes/macrophages to sites of injury (Shireman, Contreras-Shannon et al. 
2007). MCP-1 is secreted by macrophages that have been induced by pro-
inflammatory cytokines including TNF-α and IL-1β, and has been shown to play a 
role in angiogenesis following an ischemic stress (Lakshminarayanan, Lewallen et 
al. 2001). Additionally, MCP-1 exerts its effects by binding to leukocytes, and 
targeting them for activation (Yadav, Saini et al. 2010).  
MIP-1α is a pro-inflammatory cytokine and is produced by macrophages, 
lymphocytes, and dendritic cells. It is chemotactic for cells of the monocyte lineage 
as well as for lymphocytes. Additionally it appears to inhibit the proliferation of 
hematopoietic stem cells (Cook 1996).  
IL-10 is an anti-inflammatory cytokine, and is produced by monocytes, 
macrophages, dendritic cells, and lymphocytes. It is an inhibitor of antigen 
presentation, and prevents the differentiation of monocyte precursors, and the 
maturation of dendritic cells (Mosser and Zhang 2008). 
 The results of our study have confirmed that CS induces a substantial, and 
predominantly pro-inflammatory response. The initiation of the systemic 
inflammatory response should, therefore, be considered in the pathophysiology of 
CS. The systemic inflammatory response is complex and redundant therefore, the 
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exact mechanism of initiation and the interplay between cytokines and chemokines 
in CS needs to be further delineated.  
To our knowledge, this is the first study that directly confirms CS as an 
inflammatory process. The results are the beginning step, in order to extrapolate the 
mechanisms by which injury occurs. The identification of specific mediators could 
potentially serve as pharmacologic targets in future studies in an attempt to 
decrease the devastating consequences of CS. 
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CHAPTER 3: SYSTEMIC TNF-α RELEASE CONTRIBUTES TO 
MICROVASCULAR DYSFUNCTION AND TISSUE INJURY IN 
COMPARTMENT SYNDROME 
 
 
3.1 INTRODUCTION 
  
 There are few more devastating complications of musculoskeletal trauma 
than compartment syndrome (CS). CS is caused by increased pressure within a 
closed osseofascial compartment, the most common etiology being fracture of 
the lower extremity (Matsen 1975, Whitesides, Haney et al. 1975, Whitesides, 
Haney et al. 1975, Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978, 
Matsen, Winquist et al. 1980, Rorabeck 1984, Tornetta and Templeman 1997). 
Increased intra-compartmental pressure (ICP) leads to microvascular 
dysfunction, which results in limited oxygen and nutrient delivery to the tissues. 
Cellular anoxia eventually leads to myonecrosis, the sequelae of which include 
permanent functional impairment, loss of limb, and even death (Sheridan and 
Matsen 1975, Whitesides, Haney et al. 1975, Heckman, Whitesides et al. 1994, 
Fry, Wade et al. 2013).  
 In contrast to complete ischemia, CS causes myonecrosis despite vessels 
being patent: it has been demonstrated that ischemic changes occur even in the 
presence of a distal pulse (Seddon 1966). This clinical paradox suggests that the 
pathophysiology of CS is more complex than previously thought.  
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 The use of intravital video microscopy (IVVM) in animal models of 
complete limb ischemia and reperfusion (I/R) have shown that activated 
leukocytes directly impair capillary perfusion, and contribute to the parenchymal 
injury occurring with the onset of reperfusion (Forbes, Carson et al. 1995, 
Forbes, Harris et al. 1996, Harris and Skalak 1996). Previous studies by our 
group have shown a dramatic increase in leukocyte activation in the post-
capillary venules of skeletal muscle following a CS insult (Lawendy, Sanders et 
al. 2011). It has been extrapolated from this data that CS appears to induce a 
low-flow ischemic state, and due to the patent macro-circulatory system there is, 
therefore, an ongoing low-flow ischemia and reperfusion injury occurring.  
The initiation of the inflammatory pathway has been well described in the 
I/R literature, whereby activated leukocytes impair capillary perfusion and also 
result in parenchymal damage following reperfusion (Forbes, Carson et al. 1995, 
Forbes, Harris et al. 1996, Harris and Skalak 1996). Within the first hour of 
reperfusion, a peak in the pro-inflammatory cytokine, tumor necrosis factor alpha 
(TNF-α) has been reported, and it is believed to be a driving force of 
inflammation following a complete ischemic insult (Caty, Guice et al. 1990, Brock, 
Lawlor et al. 1999, Krishnadasan, Naidu et al. 2003).  TNF-α appears to act as a 
chemoattractant for neutrophils, causes up-regulation of downstream 
cytokine/chemokine production, and promotes the expression of adhesion 
molecules (Ascer, Gennaro et al. 1992, Yi and Ulich 1992, Seekamp, Warren et 
al. 1993, Krishnadasan, Naidu et al. 2003, Zhang, Hu et al. 2005).  
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It has been hypothesized that TNF-α may act as an important driving force 
of CS pathophysiology. Therefore, the purpose of this study was to evaluate the 
microvascular dysfunction, tissue injury, and inflammatory response following the 
neutralization of TNF-α at the time of fasciotomy, in an animal model of CS.  
 
 
3.2 METHODS 
 
3.2.1 Animal Handling and Care 
 
 Male Wistar rats were utilized for these experiments. Animals had access 
to food and water ad libitum. Animal housing, care, and associated protocols 
were conducted in agreement with the Canadian Council on Animal Care. The 
animal protocol for this study was approved by the Animal Use Subcommittee at 
The University of Western Ontario. 
 
 
3.2.2 Experimental Protocol 
 
 A total of twelve male Wistar rats (body weight 180 - 250g) were randomly 
assigned into three groups: (1) sham (n= 4), (2) CS (with isotype control) (n=4), 
and (3) CS with TNF-α neutralization (CS+TNF-α) (n=4). Animals were 
anesthetized with inhalational isoflurane (5% induction, 2% maintenance, titrated 
as needed to maintain an adequate level of general anesthesia) in a 1:1 O2:N2 
mixture. The left carotid artery was cannulated for continuous blood pressure 
monitoring, blood sampling, and fluid replacement. A rectal probe was inserted to 
monitor core body temperature, which was adjusted using a heat lamp, as 
needed. A normotensive and normothermic model of CS was used, where the 
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mean arterial blood pressure was maintained at 100mmHg, and core body 
temperature at 37°C. 
 
3.2.3 Compartment Syndrome 
 Isotonic saline was infused into the anterior compartment of the right hind 
limb via a 24-gauge catheter in order to elevate the ICP, as previously described 
(Lawendy, Sanders et al. 2011). The ICP was measured by an electronic 
compartmental pressure monitoring system (Synthes USA, Paoli, PA), which was 
inserted through a 14-gauge angiocatheter into the posterior compartment 
(Figure 2.1). The ICP was maintained at 30-40mmHg for 2 hours; this was 
followed by fasciotomy and 45 minutes of reperfusion. 
 Animals that underwent CS followed by isotype control for TNF-α were 
administered 0.3ml Armenian hamster IgG (3.5µg of IgG per 200g body weight, 
IV, eBioscience, SanDiego, CA) at the time of fasciotomy, while those in the 
CS+TNF-α neutralization group were administered 0.3ml TNF-α neutralizing 
antibody (3.5µg TNF-α neutralizing antibody per 200g body weight, IV, 
eBioscience, SanDiego, CA) at the time of fasciotomy. 
Sham animals underwent the same procedure as those in the CS groups; 
however the ICP was kept at the baseline level of 0mm Hg for 2 hours, followed 
by fasciotomy and 45 minutes of reperfusion.  
Intravital video microscopy (IVVM) was then performed on all animals to 
assess microvascular dysfunction, leukocyte activation and the parenchymal 
injury to the extensor digitorum longus (EDL) muscle. 
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3.2.4 Blood Sampling 
 Blood samples were collected via an indwelling carotid line. At each 
sampling time, approximately 0.3ml of blood was extracted and replaced with an 
equal volume of normal saline. Blood sampling was done as follows: (1) at the 
time of carotid artery cannulation, for baseline levels; (2) after 2 hours of CS, just 
prior to fasciotomy/antibody injection; and (3) following 45-mintues of reperfusion. 
All blood samples were allowed to coagulate on ice during the surgical procedure 
and then centrifuged at 1200xg for 15min at room temperature. Serum was 
collected and placed into clean micro-centrifuge tubes and stored at -80°C. 
 
3.2.5 Intavital Video Microscopy (IVVM) 
 Following fasciotomy, the EDL muscle was prepared for IVVM, as 
previously described (Potter, Dietrich et al. 1993, Forbes, Carson et al. 1995, 
Manjoo, Sanders et al. 2010, Lawendy, Sanders et al. 2011). The animal was 
then transferred onto the stage of an inverted microscope (Nikon, Nikon 
Instruments, Inc., Mississauga, Ontario, Canada) and the EDL muscle was 
reflected into a saline bath containing 5µg/ml each of the fluorescent vital dyes 
bisbenzimide (BB; excitation wavelength (Ex) 343 nm, emission wavelength (Em) 
483 nm) and ethidium bromide (EB; Ex 482 nm, Em 616 nm). BB stains nuclei of 
all cells while EB stains the nuclei of only those cells with damaged cell 
membranes. The EB/BB ratio, therefore, provides a measure of tissue injury.  
 Microvascular perfusion and leukocytes within the post capillary venules 
were recorded by translumination with 20x and 40x objectives respectively, in 
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five adjacent fields of view, and captured into a computer for offline video 
analysis. Fluorescence microscopy was used to visualize the BB- and EB-
labelled cells from these same fields of view. At the conclusion of the experiment, 
the rats were euthanized by an overdose of anesthetic agent. 
 
3.2.6 Offline Video Analysis 
 Capillary perfusion was assessed by counting the number of continuously 
perfused (CPC), intermittently perfused (IPC), and non-perfused (NPC) 
capillaries crossing three parallel lines drawn perpendicular to the capillary axis 
on the video monitor, and was expressed as a percentage (%) of total capillaries.  
 Tissue injury was assessed by counting the number of EB- and BB-
labelled nuclei, and expressed as EB/BB ratio.  
 Leukocyte activation was assessed by counting the number of rolling and 
adherent leukocytes in post-capillary venules, and expressed as cells per unit 
area (i.e. 1000 µm2). Venular area was measured using ImageJ software (NIH, 
Bethesda, Maryland). A leukocyte was considered adherent if it remained 
stationary for at least 30 seconds and rolling if it remained in contact with the wall 
of the vessel but did not remain stationary. 
 
3.2.7 Measurement of Serum TNF-α 
 To evaluate the effect of CS on TNF-α production, and to confirm TNF-α 
neutralisation, serum levels of TNF-α were assessed in all animals using 
enzyme-linked immunosorbent assay (ELISA) kit (Pierce Biotechnology, c/o 
	   52	  
Thermo Scientific, Rockford, IL), as per manufacturer’s instructions. The assay 
was sensitive to less than 5pg/ml. 
 
3.2.8 Statistical Analysis 
 One-way analysis of variance (ANOVA) was used to compare the degree 
of perfusion, tissue injury and leukocyte activation (both adherence and rolling). 
Repeated measures two-way ANOVA was used to compare the serum levels of 
TNF-α. Newman-Keuls multiple comparison post hoc test was used where 
appropriate (GraphPad Prism V5.0, San Diego, CA). Sample size calculation was 
performed using StatMate (GraphPad Software Inc., San Diego, CA), with power 
set at 85%. Statistical significance was defined as a p-value <0.05. 
 
 
3.3 RESULTS 
3.3.1 Microvascular Perfusion 
 The perfusion profile seen in the sham group demonstrated predominately 
continuously perfused capillaries. The perfusion profile of both the CS and the 
CS+TNF-α neutralizing groups demonstrated a shift toward IPC and NPC (Figure 
3.1). 
 The number of CPC decreased from 75.08±2.3% in the sham group to 
30.66±3.6%, and 35.7±3.5% in the CS and CS+TNF-α neutralizing groups, 
respectively (p<0.0001). There was no significant difference in CPC between the 
CS and CS+TNF-α neutralizing groups.  
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Figure 3.1. The Effect of Elevated ICP on Microvascular Perfusion in Rat 
Model of CS. CS resulted in a significant microvascular perfusion 
deficit. Neutralization of TNF-α at fasciotomy did not restore the 
microvascular perfusion (*p<0.05 from Sham; one-way ANOVA). 
CPC, continuously-perfused capillaries; IPC, intermittently-perfused 
capillaries; NPC, non-perfused capillaries. 
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The number of IPC increased from 10.76±1.5% in sham to 19.08±1.3%, 
and 25.09±2.7% in the CS and CS+TNF-α neutralizing groups, respectively 
(p<0.001). The number of IPC in the CS+TNF-α neutralizing group was 
significantly higher than that in CS group (p<0.05).  
The number of NPC increased from 14.18±1.4% in sham to 50.27±2.6%, 
and 39.19±2.8% in the CS and CS+TNF-α neutralizing groups, respectively 
(p<0.0001). The number of NPC in the CS+TNF-α neutralizing group was 
significantly lower as compared to the CS group (p<0.05). 
 
3.3.2 Tissue Injury 
 Tissue injury significantly increased following elevation of ICP, from 
0.04±0.02 in sham to 0.33±0.04 in CS group (p<0.001) (Figure 3.2). 
Administration of TNF-α neutralizing antibody resulted in a significant decrease 
when compared to CS group, to 0.21±0.04 (p<0.05). 
 
3.3.3 Leukocyte Activation 
 Elevation of ICP resulted in a significant increase in leukocyte adherence, 
from 1.7±0.4 leukocytes/30s/1000µm2 to 14.1±1.6 leukocytes/30s/1000µm2 in CS 
group (p<0.05) (Figure 3.3). Administration of TNF-α neutralizing antibody 
produced a significant decrease to 0.9±0.2 adherent leukocytes/30s/1000µm2 
(p<0.05). 
Elevation of ICP resulted in an increase in leukocyte rolling, from 2.1±0.8 
leukocytes/30s/1000µm2  in  sham to  9.8±3.2 leukocytes/30s/1000µm2  in  CS  
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Figure 3.2. Tissue Injury In a Rat Model of CS. Elevation of ICP resulted in a 
significant increase in tissue injury. Administration of a TNF-α 
neutralizing antibody at fasciotomy significantly diminished tissue 
injury (*p<0.05 from Sham, #p<0.05 from CS; one-way ANOVA). 
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Figure 3.3 Leukocyte Activation (Adhesion) in a Rat Model of CS. 
Elevation of ICP resulted in an increase in adherent leukocytes. 
Administration of TNF-α neutralizing antibody at fasciotomy blocked 
leukocyte adhesion (*p<0.0001 from Sham; one-way ANOVA). 
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Figure 3.4 Leukocyte Activation (Rolling) in a Rat Model of CS. Elevation 
of ICP resulted in a significant increase in leukocyte rolling. 
Administration of TNF-α neutralizing antibody at fasciotomy 
resulted in leukocyte rolling returning to the baseline level 
(*p<0.0001 from Sham; one-way ANOVA). 
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group (p<0.05) (Figure 3.4). Administration of TNF-α neutralizing antibody 
resulted in a significant decrease to 2.4±1.0 leukocytes/30s/1000µm2 (p<0.05). 
 
3.3.4 Serum TNF-α 
 Serum TNF-α levels in the sham animals showed no significant changes 
from the baseline level of 12.1±6.9pg/ml: serum levels of TNF-α at 2hr CS and 
45min reperfusion were 14.8±3.8pg/ml, and 12.6±5.9pg/ml respectively (p=0.357, 
n.s.) (Figure 3.5).  
 Elevation of ICP resulted in a significant increase in serum TNF-α, from 
16.1±4.8pg/ml at baseline to 1496.0±152.6pg/ml just prior to fasciotomy (p<0.05) 
(Figure 3.5). TNF-α level remained significantly elevated, at 2391.0±445.7pg/ml 
after 45 minutes of reperfusion (p<0.05). Administration of TNF-α neutralizing 
antibody at fasciotomy resulted in a complete inhibition of TNF- α, to 0pg/ml 
(p<0.05). 
 
  
3.4 DISCUSSION 
 The underlying pathophysiological mechanism of the tissue injury 
associated with acute compartment syndrome remains largely unknown. 
Previous work by our group, and others, has begun to recognize the role of the 
inflammatory pathway in microvascular compromise, and tissue injury, seen in 
CS (Manjoo, Sanders et al. 2010, Lawendy, Sanders et al. 2011, Lawendy, Bihari 
et al. 2015).  The  immune  system is  amenable  to  modulation,  and,  therefore,  
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Figure 3.5. Serum TNF-α Levels in a Rat Model of CS. Elevation of ICP 
resulted in a significant increase in systemic TNF-α, which 
continued to rise during the 45-minute reperfusion period (red line). 
Injection of TNF-α neutralizing antibody at fasciotomy resulted in a 
complete inhibition of serum TNF-α levels (blue dotted line). 
Systemic TNF-α levels remained constant in sham animals (black 
line) (*p<0.05 from baseline, †p<0.05 from CS+TNF-α group; 
repeated measures two-way ANOVA). 
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potentially represents a therapeutic target in order to decrease the tissue injury 
associated with CS. We chose to target TNF-α as it has been shown to be 
acutely elevated in complete I/R injury (Caty, Guice et al. 1990, Brock, Lawlor et 
al. 1999). 
Microvascular perfusion, under normal physiological conditions, is 
primarily that of continuous blood flow. CS causes a shift in perfusion toward 
intermittently perfused and non-perfused capillaries. An ischemic environment 
within the affected capillary bed ensues, resulting in decreased nutrient and gas 
exchange. There remains, however, continuous perfusion within a small portion 
of the capillaries, creating a low-flow ischemic environment in contrast to a 
complete ischemic state.  
 The neutralization of TNF-α essentially had no effect on the microvascular 
perfusion profile seen in CS (Figure 3.1). Tempering the inflammatory response 
did not, therefore, provide protection in restoring microvascular perfusion in the 
face of elevated compartment pressures.  These results are in keeping with the 
previous work, whereby a leukocyte-deplete animal model was not shown to be 
protective in restoring the microvascular perfusion following a CS insult 
(Lawendy, Bihari et al. 2015). A distinction with complete I/R must again be 
highlighted: microvascular dysfunction was prevented, and parenchymal injury 
was reduced in a leukocyte deplete I/R model (Forbes, Harris et al. 1996). This 
data further corroborates that the microvascular dysfunction associated with 
compartment syndrome has a distinct pathophysiology compared to that of 
complete ischemia-reperfusion.  
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 The results of our study confirm that CS induces a systemic inflammatory 
response. Elevation of ICP for 2 hours resulted in a significant increase in serum 
TNF-α, coupled with the recruitment of activated leukocytes, and arrest of 
leukocytes, observed under live microscopy (Figure 3.5). Blocking the 
inflammatory response post-fasciotomy, through the administration of TNF-α 
neutralizing antibody, significantly decreased leukocyte activation, as evidenced 
by a decrease in both rolling and adherent leukocytes within the post-capillary 
venules (p<0.05 and p<0.0001 respectively) (Figure 3.3 and Figure 3.4). 
Activated leukocytes are known to produce reactive oxygen species and 
proteolytic enzymes; this results in an increased vascular permeability and tissue 
edema, cellular injury, and raised interstitial pressure. Combined, the effects may 
exacerbate perfusion dysfunction in the microvascular bed.  
 In this study, elevation of ICP resulted in a significant increase in the 
number of EB-labelled nuclei (i.e. tissue injury). Neutralization of TNF-α led to a 
significant relative reduction of approximately 36% in tissue injury (Figure 3.2). 
This data confirms that TNF-α plays at least some role in the inflammatory 
response observed in a CS insult. In a leukocyte-deplete animal model of CS, 
tissue injury was reduced by more than 50%, implying that there are also other 
cytokines/chemokines involved in the pathophysiology of CS (Lawendy, Bihari et 
al. 2015). 
 Leukocyte activation within the post capillary venules appears to play a 
role in producing the tissue injury observed in CS, without directly affecting the 
perfusion profile of the microvascular beds. In the early phase of CS, at least, 
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TNF-α plays a role in the tissue injury associated with CS. Neutralizing TNF-α in 
isolation had less of an effect on reducing tissue injury in comparison to a 
completely leukocyte deplete animal model, again suggesting a role for also 
other cytokines/chemokines in the pathophysiology of CS (Lawendy, Bihari et al. 
2015).  
 The study validates immune modulation as a potential therapeutic target in 
order to diminish the parenchymal injury associated with CS. While TNF-α is only 
one of many cytokines/chemokines in a complex and redundant system, its 
neutralization did result in a significant decrease in tissue injury. Continued 
investigation is still required, as this is only one small piece of a complex 
pathophysiological mechanism.  
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Chapter 4 
 
General Discussion and Conclusions. 
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CHAPTER 4: GENERAL DISCUSSION AND CONCLUSIONS 
 
4.1 OVERVIEW OF RESULTS 
4.1.1 Pathophysiology of Compartment Syndrome 
 Compartment syndrome (CS) remains one of the most devastating 
complications of musculoskeletal trauma. It occurs secondary to elevated 
pressure within a closed osseofascial compartment, and is both a limb and life-
threatening condition (McQueen, Gaston et al. 2000, Hayakawa, Aldington et al. 
2009). Despite being a recognized complication of trauma since Richard von 
Volkmann’s description of ischemic contracture in the upper limb of children in 
1881, to date the underlying pathophysiological mechanism remains largely 
unknown (von Volkmann 1881). 
 Raised intra-compartmental pressure (ICP) is the initial insult seen in CS, 
which then leads to microvascular dysfunction, hypo-perfusion of the tissues, and 
ultimately cellular anoxia and cell death (Sheridan and Matsen 1975, Whitesides, 
Haney et al. 1975, Rorabeck and Clarke 1978, Harvey, Sanders et al. 2012). 
There are a few important distinctions that must be drawn between CS and 
complete ischemia-reperfusion (I/R) injury: CS causes tissue necrosis despite a 
patent macrocirculatory system, where ischemic tissue injury occurs in the face 
of a palpable distal pulse (Seddon 1966), and a CS insult is more injurious than a 
complete ischemic insult of the same duration (Heppenstall, Scott et al. 1986). 
These findings suggest that the pathophysiology of CS involves a low-flow 
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ischemic state, is more complex than previously understood, and is distinct from 
that of complete I/R injury. 
 
4.1.2 Compartment Syndrome as Low-Flow Ischemia 
 Under normal conditions, microvascular perfusion exhibits predominantly 
continuously perfused capillaries (CPC). Raised ICP has been shown to cause a 
shift in perfusion toward intermittently perfused capillaries (IPC), and non-
perfused capillaries (NPC) (Lawendy, Sanders et al. 2011, Lawendy, Bihari et al. 
2015). The presence of CPC in the same muscle bed as IPC and NPC suggests 
that CS induces a low-flow ischemic state, as there is some degree of continuous 
perfusion still present. Ischemia ensues as a consequence of inefficient nutrient 
and gas exchange to meet the metabolic demands of the tissue, despite some 
continuous oxygen delivery (Lawendy, Sanders et al. 2011). We believe that this 
ongoing perfusion in the face of an essentially ischemic tissue bed is analogous 
to the reperfusion injury associated with complete I/R injury. The presence of 
oxygen in ischemic tissue results in the generation of reactive oxygen 
metabolites, the initiation of an acute inflammatory state, and triggers cellular 
death via apoptosis and necroptosis (Gute, Ishida et al. 1998, Lum and Roebuck 
2001). This pattern of tissue injury is, however, distinct from that of complete I/R, 
which has defined phases of injury (ischemia, then reperfusion).  We believe the 
low-flow ischemic state associated with CS initiates an early and continuous 
reperfusion injury, which not only persists for the duration of the raised ICP, but is 
exacerbated by fasciotomy and the restitution of blood flow to the capillary beds. 
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Heppenstall et al (1986) have demonstrated, in a canine model, that a CS insult 
is more injurious than a complete ischemic insult of the same duration, further 
corroborating our theory that CS incudes an early and continuous state of 
reperfusion injury. 
 The first aim of this thesis was to confirm that CS induces the systemic 
inflammatory response, and to examine the specific cytokines/chemokines 
released as a result. A further focus of this thesis was to evaluate the 
microvascular dysfunction, tissue injury, and inflammatory response following the 
neutralization of TNF-α at the time of fasciotomy. The background for these 
studies has been primarily extrapolated from I/R literature and, more recently, 
from studies by our group; thus the role of inflammation in CS-induced tissue 
injury is beginning to be recognized. 
 
4.1.3 Compartment Syndrome as an Inflammatory Process 
 The study was designed to confirm that CS is associated with the initiation 
of a systemic inflammatory response, and to examine the suspected 
inflammatory cytokine/chemokine release in response to CS. The initiation of the 
inflammatory response has been well described following complete I/R injury, 
however, to our knowledge, had not been studied to-date in CS. The use of IVVM 
imaging of the capillaries following CS has demonstrated significant 
microvascular dysfunction, concurrent with a significant increase in leukocyte 
activation in the post-capillary venules of skeletal muscle (Lawendy, Bihari et al. 
2015). These findings suggested that CS induces a pro-inflammatory 
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environment; however, the specific cytokines/chemokines involved remained 
unknown. Following a complete I/R injury, activated leukocytes in the post-
capillary venules have been shown to directly inhibit capillary perfusion, cause 
direct parenchymal damage following the onset of reperfusion, increase vascular 
permeability, and increase tissue edema (Kurose, Anderson et al. 1994, Forbes, 
Harris et al. 1996, Harris and Skalak 1996).  
Our study confirmed that CS induced a systemic cytokine/chemokine 
release. Twenty-four cytokines/chemokines were measured, and 14 were 
detectable. Of the 14 detected, 12 were pro-inflammatory, 1 was anti-
inflammatory, and 1 had both a pro- and an anti-inflammatory effect. Six of the 14 
cytokines/chemokines that were detectable were significantly elevated from their 
baseline levels after 2hrs of CS (p<0.05). These included TNF-α (Figure 2.2), IL-
1β (Figure 2.3), GRO/KC (Figure 2.4), MCP-1 (Figure 2.5), MIP-1α (Figure 2.6), 
and IL-10 (Figure 2.7). TNF-α, IL-1β, GRO/KC, MCP-1, and MIP-1α are pro-
inflammatory cytokines/chemokines, while IL-10 is an anti-inflammatory cytokine. 
These results confirm that CS induces a significant and, predominantly, pro-
inflammatory response.  
 
4.1.4 TNF-α Neutralization  
 The purpose of this study was to evaluate the microvascular dysfunction, 
inflammatory response, and tissue injury following the neutralization of TNF-α at 
the time of fasciotomy, in an animal model of CS. TNF-α is a potent pro-
inflammatory cytokine released in response to trauma, inflammation, or infectious 
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stimulation (Stein and Gordon 1991). Previously, multiple I/R studies have 
demonstrated that TNF-α is up-regulated in as little as 1 hour following 
reperfusion (Caty, Guice et al. 1990, Brock, Lawlor et al. 1999, Krishnadasan, 
Naidu et al. 2003). TNF-α acts as a chemoattractant for neutrophils, causes up-
regulation of downstream cytokine/chemokine production, promotes the 
expression of adhesion molecules, and activates cell death via apoptosis and 
necroptosis (Ascer, Gennaro et al. 1992, Yi and Ulich 1992, Seekamp, Warren et 
al. 1993, Zhang, Hu et al. 2005, Parameswaran and Patial 2010). 
  CS causes a shift in perfusion from CPC (under normal physiological 
conditions) to that of IPC and NPC. The neutralization of TNF-α at the time of 
fasciotomy essentially had no effect on the microvascular perfusion profile seen 
in CS (Figure 3.1). Modulation of the inflammatory response did not, therefore, 
provide protection in restoring microvascular perfusion in the face of raised ICP.  
These results corroborate previous work by our group, whereby a leukocyte-
deplete animal model was not shown to be protective in restoring the 
microvascular perfusion following a CS insult (Lawendy, Bihari et al. 2015).  
 The results of this study, again, confirm that CS induces a systemic 
inflammatory response. Two hours of CS produced a significant increase in 
serum TNF-α, coupled with the recruitment of activated leukocytes (Figure 3.5). 
Modifying the inflammatory response post-fasciotomy, through the administration 
of TNF-α neutralizing antibody, significantly decreased leukocyte activation, as 
evidenced by a decrease in both rolling and adherent leukocytes within the post-
capillary venules (p<0.05 and p<0.0001 respectively) (Figure 3.3 and Figure 3.4).  
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 When compared to control animals, neutralization of TNF-α led to a 
significant relative reduction of approximately 36% in tissue injury (Figure 3.2) 
following elevated ICP. This data confirms that TNF-α plays at least some role in 
the inflammatory response observed in a CS insult. In a leukocyte-deplete animal 
model of CS, tissue injury was reduced by more than 50%, implying that there 
are also other cytokines/chemokines involved in the pathophysiology of CS 
(Lawendy, Bihari et al. 2015). 
 Our findings confirm that CS is associated with a significant up-regulation 
of the systemic inflammatory response, and its induction should, therefore, be 
considered in the pathophysiology of CS. TNF-α plays a role in the tissue injury 
associated with CS, at least in the acute phase. Neutralizing TNF-α in isolation 
had less of an effect on reducing tissue injury in comparison to a completely 
leukocyte deplete animal model, suggesting that other cytokines/chemokines 
may also contribute to the pathophysiology of CS (Lawendy, Bihari et al. 2015). 
There are, of course, multiple potential mechanisms of tissue injury, including the 
generation of reactive oxygen species, increased expression of adhesion 
molecules on the surface of leukocytes and endothelial cells, and direct 
parenchymal injury via extravasated leukocytes (Gute, Ishida et al. 1998).  
 TNF-α as been recognized in initiating cell death via apoptosis and 
necroptosis (Wu, Tan et al. 2011). Necroptosis, in particular, is associated with 
pathological conditions including I/R; and, in contrast to apoptosis, it generates 
an inflammatory response (Vandenabeele, Galluzzi et al. 2010, Linkermann and 
Green 2014). It is, therefore, plausible that the low-flow ischemia associated with 
	  	  
72	  
CS, and consequently the early and sustained reperfusion injury, stimulates an 
earlier and sustained trigger of the apoptotic and necroptotic pathways. This 
could in part, account for the greater tissue injury associated with CS versus 
complete I/R.  
 
4.2 LIMITATIONS AND FUTURE DIRECTIONS 
 Inflammation has been shown to play an important role in the 
microvascular dysfunction and tissue injury associated with CS. One of the 
limitations of these studies is its use of a small animal model. The injury process 
and clinical significance of the observed decrease in tissue injury remain to be 
translated to a human model. Future directions would include a large animal 
model, whose physiology more resembles that of humans, and recovery studies 
in order to assess functional outcomes. 
The study also validates immune modulation as a potential therapeutic 
target in order to decrease the tissue injury associated with CS. TNF-α is already 
a mainstay of treatment in chronic pro-inflammatory conditions, such as Crohn’s 
disease, rheumatoid arthritis, and psoriasis (Ford, Sandborn et al. 2011). TNF-α 
is only one of many cytokines/chemokines that were found to be significantly up-
regulated following CS. Targeting different cytokines/chemokines, or a 
combination of them, could further elucidate the pathophysiological mechanism 
of CS. 
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4.3 CONCLUSIONS 
The maintenance of microvascular perfusion throughout the CS insult 
allows oxygenated blood to enter an essentially ischemic compartment, which 
ultimately leads to the early initiation of the inflammatory cascade, and activation 
of leukocytes. This, in turn, stimulates the release of predominantly pro-
inflammatory cytokines/chemokines, and in particular, the production of TNF-α. 
Neutralization confirms that TNF-α plays a role in the tissue injury associated 
with CS, likely through early activation of the apoptotic and necroptotic pathways.  
The systemic inflammatory response is a complex and redundant system, 
and continued investigation is still required, as this study has only begun to 
elucidate one small piece of a complex pathophysiological mechanism. 
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APPENDIX A: ANIMAL PROTOCOL APPROVAL LETTER 
	  	  	  	  	  	  	  	  	   	   	   	   	   	   	   	   	   	   	  	   11.01.13	  	   	   	   	   	   	   *This	  is	  the	  original	  approval	  for	  this	  protocol*	  *A	  full	  protocol	  submission	  will	  be	  required	  in	  2017*	  	  Dear	  Dr.	  Lawendy:	  	  Your	  animal	  use	  protocol	  form	  entitled:	  	  Direct	  and	  Remote	  Organ	  Injury	  Following	  Hind	  Limb	  Compartment	  Syndrome	  	  Funding	   agency	   Orthopaedic	   Trauma	   Association	   –	   Direct	   and	   Remote	   Organ	   Injury	   Following	   Hind	   Limb	  Compartment	  Syndrome	  –	  Grant	  #R4889A04	  has	  been	  approved	  by	  the	  University	  Council	  on	  Animal	  Care.	  	  This	  approval	  is	  valid	  from	  11.01.13	  to	  11.30.17	  with	  yearly	  renewal	  required.	  	  The	  protocol	  number	  for	  this	  project	  is	  2009-­‐083.	  	  1.	  	  This	  number	  must	  be	  indicated	  when	  ordering	  animals	  for	  this	  project.	  2.	  	  Animals	  for	  other	  projects	  may	  not	  be	  ordered	  under	  this	  number.	  3.	  	  If	  no	  number	  appears	  please	  contact	  this	  office	  when	  grant	  approval	  is	  received.	  If	   the	   application	   for	   funding	   is	   not	   successful	   and	   you	  wish	   to	   proceed	  with	   the	   project,	   request	   that	   an	  internal	  scientific	  peer	  review	  be	  performed	  by	  the	  Animal	  Use	  Subcommittee	  office.	  4.	   	   Purchases	   of	   animals	   other	   than	   through	   this	   system	   must	   be	   cleared	   through	   the	   ACVS	   office.	   Health	  certificates	  will	  be	  required.	  	  
ANIMALS	  APPROVED	  FOR	  4	  YEARS	  
Species Strain Other Detail Pain 
Level 
Animal # Total 
for 4 years 
Rat Wistar 150-350 g C 680 
Pig Yorkshire-Landrace 50-60 kg B 30 	  
REQUIREMENTS/COMMENTS	  Please	   ensure	   that	   individual(s)	   performing	   procedures	   on	   live	   animals,	   as	   described	   in	   this	   protocol,	   are	  familiar	  with	  the	  contents	  of	  this	  document.	  	  The	  holder	  of	  this	  Animal	  Use	  Protocol	  is	  responsible	  to	  ensure	  that	  all	  associated	  safety	  components	  (biosafety,	  radiation	   safety,	   general	   laboratory	   safety)	   comply	   with	   institutional	   safety	   standards	   and	   have	   received	   all	  necessary	  approvals.	  Please	  consult	  directly	  with	  your	  institutional	  safety	  officers.	  	  	  	  	  	  	  	  
c.c.	  	  R	  Bihari,	  T	  Carter,	  K	  Bothwell,	  P	  Coakwell	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Dear Dr Erin Donohoe 
We hereby grant you permission to reproduce the material detailed below at no charge in your thesis, in 
print and on Western Library’s Scholarship@Western program.subject to the following conditions:  
1.         If any part of the material to be used (for example, figures) has appeared in our publication 
with credit or acknowledgement to another source, permission must also be sought from that 
source.  If such permission is not obtained then that material may not be included in your 
publication/copies. 
2.         Suitable acknowledgment to the source must be made, either as a footnote or in a reference 
list at the end of your publication, as follows: 
“This article was published in Publication title, Vol number, Author(s), Title of article, Page Nos, 
Copyright Elsevier (or appropriate Society name) (Year).”  
3.         Your thesis may be submitted to your institution in either print or electronic form. 
4.         Reproduction of this material is confined to the purpose for which permission is hereby 
given. 
5.         This permission is granted for non-exclusive world English rights only.  For other 
languages please reapply separately for each one required.  Permission excludes use in an 
electronic form other than as specified above.  Should you have a specific electronic project in 
mind please reapply for permission. 
6.         This includes permission for the Library and Archives of Canada to supply single copies, 
on demand, of the complete thesis.  Should your thesis be published commercially, please reapply 
for permission. 
  
Yours sincerely 
 
Jennifer Jones  
Permissions Specialist 
Elsevier Limited, a company registered in England and Wales with company number 1982084, whose 
registered office is The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom. 
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APPENDIX C: SURGICAL APPROACH TO LEG COMPARTMENT 
SYNDROME 
 
 
There are multiple surgical techniques for complete fascial release of the 
lower leg. These include a two-incision fasciotomy, a single-incision perifibular 
fasciotomy, and fibulectomy.  The preferred method is the two-incision technique 
(described below), as it allows for adequate visualization of all compartments, 
assessment of muscle viability, and sufficient exposure to safely avoid injury to 
the neurovascular structures. 
 
C1. Two-Incision Fasciotomy (Mubarak and Hargens 1981) 
The patient is positioned supine on the operating room table. A tourniquet 
is applied above the knee, but not insufflated. The limb is prepped and draped 
free. A 25 cm incision is made, centered halfway between the fibular shaft and 
the tibial crest (Figure C1). The subcutaneous tissue is dissected and full 
thickness skin flaps are elevated in order to achieve wide exposure of the fascial 
compartments. The intermuscular septum is exposed, and the superficial 
peroneal nerve is identified distally, lying posterior to the septum. Using 
dissecting scissors, the anterior compartment is released proximally and distally, 
in line with the tibialis anterior. The lateral compartment is released proximally 
and distally, in line with the fibular shaft. Care must be taken at the distal end to 
avoid damaging the superficial peroneal nerve. 
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A second longitudinal incision 2 cm posterior to the posterior margin of the 
tibia is made. The subcutaneous tissue is dissected, and full thickness skin flaps 
are elevated for exposure. The saphenous vein and nerve are identified and 
protected. The septum between the deep and superficial posterior compartments 
is identified. The superficial posterior compartment is released by incising the 
fascia along the entire length of the gastrocnemius-soleus complex. The deep 
posterior compartment is released by incising the fascia over the flexor digitorum 
longus muscle. Proximally, if the soleus bridge extends more than halfway down 
the tibia, this extended origin must be released. Finally, after release of the 
posterior compartment the tibialis posterior muscle must be identified. If there is 
increased tension within this compartment, it is released. 
Wounds are left open and packed, and a posterior plaster splint is applied 
with the foot plantigrade. 
 
 
C2. REFERENCES 
 
Lawendy, A. and D. Sanders (2010). Operative Techniques: Orthopaedic Trauma 
Surgery, Saunders. 
 
Mubarak, S. J. and A. R. Hargens (1981). Compartment syndromes and 
Volkmann's ischemic contracture. Philadelphia, WB Saunders. 
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Figure C1. Two-Incision Fasciotomy. An incision is made halfway between 
the fibular shaft and the crest of the tibia. The lateral intermuscular 
septum is exposed and the superficial peroneal nerve is identified. 
The anterior compartment is released by incising the fascia in line 
with the tibialis anterior. The lateral compartment is released by 
incising the fascia in line with the fibular shaft. A second incision is 
made 2 cm posterior to the posterior margin of the tibia. The 
superficial posterior compartment is released by incising the fascia 
over the entire length of the gastrocnemius-soleus complex. Finally, 
the deep posterior compartment is released with a fascial incision 
overlying the flexor digitorum longus muscle. 
Reproduced with permission from Lawendy and Sanders (2010). 
!
! 146!
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D2: Two-incision fasciotomy. An incision in the anterior compartment is 
centered halfway between the fibular shaft and the crest of the tibia. Lateral 
intermuscular septum is exposed and the superficial peroneal nerve is identified. 
The anterior compartment is released proximally and distally in line with the 
tibialis anterior. Fasciotomy of the lateral compartment proximally and distally in 
line with the fibula  shaft is performed.  A second longitudi al incision 2 cm 
posterior to the posterior margin of the tibia is made; fascia over the 
gastrocsoleus complexis released over its entire length. Then, the deep posterior 
compartment is released via fascial incision over the flexor digitorum longus.  
Reproduced with permission from Lawendy and Sanders (2010). 
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APPENDIX D: LUMINEX x-MAP ASSAY PROTOCOL 
 
Sera were subjected to a cytokine/chemokines multiplex panel 
(MILIPLEX® MAP, EMD Millipore, St. Charles, MO), based on Luminex® x-MAP 
technology, simultaneously quantifying the expression of 24 different 
cytokines/chemokines: Eotaxin, G-CSF, GM-CSF, IL-1α, MCP-1, leptin, MIP-1α, 
IL-4, IL-1β, IL-2, IL-6, IL-9, IL-13, IL-10, IL-12p70, IL-5, IFN-γ, IL-17, IL-18, IP-10, 
GRO/KC, RANTES, TNF-α, VEGF. This immunoassay technology uses 
fluorescently labelled microsphere beads. 
In principle, internally colour-coded microspheres are coated with two 
fluorescent dyes. Through precise concentrations of these, a hundred distinctly 
coloured bead sets can be created, each of which is coated with a specific 
capture antibody. After an analyte from a test sample is captured by the bead, a 
biotinylated detection antibody is introduced. The reaction mixture is then 
incubated with the reporter conjugate (streptavidin-phycoerythrin) to complete the 
reaction on the surface of each microsphere. The microspheres are allowed to 
pass rapidly through a laser, which excites the internal dyes marking the 
microsphere set. A second laser excites phycoerythrin, the fluorescent dye on 
the reporter molecule. Finally, high-speed digital-signal processors identify each 
individual microsphere and quantify the result of its bioassay based on 
fluorescent reporter signals, comparing it to the standard curve. 
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All samples were run in duplicate. Standard curve was obtained by 
performing serial dilutions of rat standard containing all 24 cytokines/chemokines; 
20,000pg/ml, 5,000pg/ml, 1,250pg/ml, 312.5pg/ml, 78.13pg/ml, 19.53pg/ml, 
4.88pg/ml and 0pg/ml were used to run the standard curve. 25µl of each sample 
or standard, followed by 25µl of beads were added to the appropriate wells on a 
96-well plate, and incubated with agitation overnight at 4°C. Following two 
washes with the wash buffer, 25µl of detection antibody were added to each well, 
and incubated for 2 hours at room temperature. This was followed by addition of 
25µl of phycoerythrin to each well and 30-minute incubation at room temperature. 
The plate was washed two times with wash buffer; 150µl of sheath fluid was then 
added to each well to reconstitute the microbeads. The plate was then read on 
Luminex200 instrument equipped with MILLIPLEX® Analyst 5.1 software, 
recording the median fluorescent intensity (MFI). The results were calculated by 
4-point logistic curve fitting software against the MFI of the standards. 
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